Biomedical Engineering Reference
In-Depth Information
8. Zhou Q, Sparreboom A, Tan EH, Cheung YB, Lee A, Poon D, Lee EJ, Chowbay B. 2005.
Pharnacogenetic profiling across the irinotecan pathway in Asian patients with cancer.
Br J Clin Pharmacol 59: 415-424.
9. de Jong FA, de Jonge MJ, Verweij J, Mathijssen RH. 2006. Role of pharmacogenetics in
irinotecan therapy. Cancer Lett 234: 90-106.
10. Yamaguchi H, Hishinuma T, Endo N, Tsukamoto H, Kishikawa Y, Sato M, Murai Y,
Hiratsuka M, Ito K, Okamura C, et al. 2006. Genetic variation in ABCB1 influences pa-
clitaxel pharmacokinetics in Japanese patients with ovarian cancer. Int J Gynecol Cancer
16: 979-985.
11. Henningsson A, Marsh S, Loos WJ, Karlsson MO, Garsa A, Mross K, Mielke S, Vigano
L, Locatelli A, Verweij J, Sparreboom A, McLeod HL. 2005. Association of CYP2C8,
CYP3A4, CYP3A5, and ABCB1 polymorphisms with the pharmacokinetics of paclitaxel.
Clin Cancer Res 11: 8097-8104.
12. Verstuyft C, Schwab M, Schaffeler E, Kerb R, Brinkmann U, Jaillon P, Funck-Brentano
C, Becquemont L. 2003. Digoxin pharmacokinetics and MDR1 genetic polymorphisms.
Eur J Clin Pharmacol 58: 809-812.
13. Schwab M, Eichelbaum M, Fromm MF. 2003. Genetic polymorphisms of the human
MDR1 drug transporter. Annu Rev Pharmacol Toxicol 43: 285-307.
14. Siddiqui A, Kerb R, Weale ME, Brinkmann U, Smith A, Goldstein DB, Wood NW,
Sisodiya SM. 2003. Association of multidrug resistance in epilepsy with a polymorphism
in the drug-transporter gene ABCB1. N Engl J Med 348: 1442-1448.
15. Wada M. 2006. Single nucleotide polymorphisms in ABCC2 and ABCB1 genes and their
clinical impact in physiology and drug response. Cancer Lett 234: 40-50.
16. Siegsmund M, Brinkmann U, Schaffeler E, Weirich G, Schwab M, Eichelbaum M, Fritz
P, Burk O, Decker J, Alken P, et al. 2002. Association of the P-glycoprotein transporter
MDR1(C3435T) polymorphism with the susceptibility to renal epithelial tumors. J Am
Soc Nephrol 13: 1847-1854.
17. Drozdzik M, Bialecka M, Mysliwiec K, Honczarenko K, Stankiewicz J, Sych Z. 2003.
Polymorphism in the P-glycoprotein drug transporter MDR1 gene: a possible link between
enviromental and genetic factors in Parkinson's disease. Pharmacogenetics 13: 259-
263.
18. Furuno T, Landi MT, Ceroni M, Caporaso N, Bernucci I, Nappi G, Martignoni E,
Schaffeler E, Eichelbaum M, Schwab M, Zanger UM. 2002. Expression polymorphism
of the blood-brain barrier component P-glycoprotein (MDR1) in relation to Parkinson's
disease. Pharmacogenetics 12: 529-534.
19. Schwab M, Schaffeler E, Marx C, Fromm MF, Kaskas B, Metzler J, Stange E, Herfarth
H, Schoelmerich J, Gregor M, et al. 2003. Association between the C3435T MDR1 gene
polymorphism and susceptibility for ulcerative colitis. Gastroenterology 124: 26-33.
20. Fellay J, Marzolini C, Meaden ER, Back DJ, Buclin T, Chave JP, Decosterd LA, Furrer
H, Opravil M, Pantaleo G, et al. 2002. Response to antiretroviral treatment in HIV-
1-infected individuals with allelic variants of the multidrug resistance transporter 1: a
pharmacogenetics study. Lancet 359: 30-36.
21. Nasi M, Borghi V, Pinti M, Bellodi C, Lugli E, Maffei S, Troiano L, Richeldi L, Mussini
C, Esposito R, Cossarizza A. 2003. MDR1 C3435T genetic polymorphism does not
influence the response to antiretroviral therapy in drug-naive HIV-positive patients. AIDS
17: 1696-1698.
Search WWH ::
Custom Search